• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

    4/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email

    BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) expected to be filed in the third quarter of 2025.

    "As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease," said Luca Passamonti, MD, PhD, Neuroscience Medical Director, Lantheus. "Tools like MK-6240 offer more than just clarity — they provide precision. By identifying tau accumulation early and accurately, we have the potential to improve diagnostic confidence, tailor patient care, and, through monitoring, ultimately change what we know about the trajectory of disease progression. This level of insight has long been missing in the field, and MK-6240, a next-generation imaging agent, has the potential to fill that critical gap."

    "The clinical results of MK-6240 underscore our commitment to providing cutting-edge imaging solutions for Alzheimer's disease that align with the latest scientific advancements," said Brian Markison, CEO, Lantheus. "With MK-6240 successfully meeting its primary endpoints in both pivotal studies, we are moving closer to delivering this innovative radiodiagnostic to potentially support precise diagnoses and improve disease management."

    MK-6240 is designed to target aggregated tau protein in the form of neurofibrillary tangles (NFTs), a key hallmark of several neurodegenerative diseases, including Alzheimer's disease. The successful completion of these studies represents the next step in advancing MK-6240 as a potential tool to aid in the diagnosis, staging, and monitoring of Alzheimer's disease.

    The development of MK-6240 complements Lantheus' ß amyloid PET imaging agent, NAV-4694 (F18-flutafuranol), which is currently in Phase 3 development and is actively utilized in both academic and industry-led investigational therapeutic trials for Alzheimer's disease. Together, these imaging agents, if approved, will further position Lantheus as the leader in radiopharmaceutical innovation, supporting the evolving diagnostic landscape for neurodegenerative conditions.

    Driven by rising prevalence, more treatment options, and expanded PET imaging guidelines, the U.S. Alzheimer's Disease radiodiagnostic market has the potential to reach over 400,000 scans and $1.5 billion by 2030.1 It is estimated that there are over 100 therapies in clinical development targeting either beta amyloid or tau.

    About Alzheimer's Disease

    Alzheimer's disease is a degenerative neurological disorder that causes a decline in cognition and function. In the U.S., there are nearly 12 million people living with mild cognitive impairment or Alzheimer's disease. As the population ages, it is likely that the prevalence of this disease will continue to rise and, by 2050, the number of people aged 65 and older with mild cognitive impairment and Alzheimer's disease may grow to more than 20 million.2

    About MK-6240

    MK-6240 is designed to target aggregated tau protein in the form of neurofibrillary tangles (NFTs), a key hallmark of several neurodegenerative diseases, including Alzheimer's disease. MK-6240 has demonstrated a high affinity for tau and limited off-target binding in both preclinical and clinical studies.3,4 Acquired by Lantheus in 2023, MK-6240 has received Fast Track designation and is currently being used in over 100 active clinical trials. We anticipate that MK-6240 will support earlier disease detection, patient staging, therapy selection, and monitoring, and may help enable tau to serve as a surrogate endpoint for treatment efficacy. Lantheus expects to file an NDA with the FDA in the third quarter of 2025.

    About Lantheus

    Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.

    Safe Harbor for Forward-Looking and Cautionary Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "continue," "expects," "may," "moving closer," "plans," "poised," "position,""potential," "will," and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) a delay in obtaining, or failure to obtain, a positive regulatory outcome from the FDA for MK-6240; (ii) our ability to launch MK-6240 as a commercial product; (iii) the market receptivity to MK-6240 as a radiopharmaceutical diagnostic; (iv) the existence, availability and profile of competing products; (v) our ability to obtain and maintain adequate coding, coverage and payment for MK-6240; (vi) the safety and efficacy of MK-6240; (vii) the intellectual property protection of MK-6240; (viii) our ability to successfully develop and scale the manufacturing capabilities to support the launch of MK-6240; and (ix) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the RiskFactors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).

    1Addressable market based on current management estimates, internal data, and current WAC / 340B pricing.

    2Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures. Alzheimer's Dement 2024;20(5).

    3Krishnadas N, Doré V, Robertson JS, Ward L, Fowler C, Masters CL, Bourgeat P, Fripp J, Villemagne VL, Rowe CC. Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK-6240 PET study. EBioMedicine. 2023 Feb;88:104450. doi: 10.1016/j.ebiom.2023.104450. Epub 2023 Jan 27. PMID: 36709581; PMCID: PMC9900352.

    4Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, Reynders T, Telan-Choing NF, Riffel K, Celen S, Serdons K, Bormans G, Tsai K, Walji A, Hostetler ED, Evelhoch JL, Van Laere K, Forman M, Stoch A, Sur C, Struyk A. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019 Jan;60(1):107-114. doi: 10.2967/jnumed.118.208215. Epub 2018 Jun 7. PMID: 29880509.

    Contacts:



    Lantheus

    Mark Kinarney

    Vice President, Investor Relations

    978-671-8842

    [email protected]

    Melissa Downs

    Executive Director, External Communications

    646-975-2533

    [email protected]



    Primary Logo

    Get the next $LNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    11/30/2022Outperform
    SVB Leerink
    More analyst ratings

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

      Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year

      5/7/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Announces Sale of SPECT Business to SHINE Technologies

      Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreement to sell its single photon emission computed tomography (SPECT) business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC (collectively, "SHINE"). Under the terms of

      5/6/25 4:01:00 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

      BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application (NDA) submission to the U.S. Food and Drug Admin

      4/30/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 8:21:14 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

      SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      11/14/24 3:29:28 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Lantheus Holdings Inc.

      SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

      2/14/24 1:18:20 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

      SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      5/8/25 4:09:31 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Lantheus Holdings Inc.

      10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)

      5/7/25 7:41:26 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Lantheus Holdings, Inc. (0001521036) (Filer)

      5/7/25 7:38:14 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

      BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

      1/30/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Appoints Julie Eastland as New Board Member

      BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t

      9/5/24 8:30:00 AM ET
      $DVAX
      $LNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Lantheus Appoints Jamie Spaeth as Chief People Officer

      BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "We're excited to have Jamie join Lantheus as we continue to harness our team's potential to deliver innovative solutions to serve patients and healthcare professionals," said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. "At Lantheus, our people drive our success, and Jamie's proven leadership and expertise will foster a collaborativ

      7/8/24 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Blanchfield Paul covered exercise/tax liability with 455 shares, decreasing direct ownership by 0.38% to 118,391 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      4/21/25 4:11:52 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Officer Niedzwiecki Daniel covered exercise/tax liability with 178 shares, decreasing direct ownership by 0.18% to 99,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      4/21/25 4:11:36 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Accounting Officer Brown Kimberly was granted 3,433 shares, increasing direct ownership by 73% to 8,164 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      3/21/25 6:48:15 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Lantheus Holdings with a new price target

      Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00

      12/18/24 7:37:47 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Redburn Atlantic initiated coverage on Lantheus Holdings with a new price target

      Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00

      9/3/24 8:07:35 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JMP Securities reiterated coverage on Lantheus Holdings with a new price target

      JMP Securities reiterated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $130.00 from $100.00 previously

      7/10/24 3:24:56 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Financials

    Live finance-specific insights

    See more
    • Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update

      Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year

      5/7/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

      BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About Lan

      4/23/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance

      Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high

      2/26/25 7:00:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care